期刊
TARGETED ONCOLOGY
卷 9, 期 3, 页码 239-249出版社
SPRINGER
DOI: 10.1007/s11523-013-0290-9
关键词
Cancer stem cells; Targeted toxins; Immunotoxins; CD133; EpCAM; Head and neck squamous cell carcinoma
类别
资金
- US Public Health Service - NCI [R01-CA36725]
- NIAID, DHHS
- Randy Shaver Foundation
- Atwater Cancer Drug Development Award
- CETI translational award from the University of Minnesota Masonic Cancer Center
The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC markers on the same cell killing this resistant subpopulation. CD133 is a well-known CSC marker and has been successfully targeted and caused regression of head and neck squamous cell carcinoma (HNSCC) in vivo. To enable it to bind a broader range of CSCs, an anti-epithelial cell adhesion molecule (EpCAM) scFv was added to create dEpCAMCD133KDEL, a deimmunized bispecific targeted toxin on a single amino acid chain. This bispecific potently inhibited protein translation and proliferation in vitro in three different types of carcinoma. Furthermore, in a CSC spheroid model dEpCAMCD133KDEL eliminated Mary-X spheroids, an inflammatory breast carcinoma. Finally, this bispecific also caused tumor regression in an in vivo model of HNSCC. This represents the first bispecific CSC-targeted toxin and warrants further development as a possible therapy for carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据